Lactoferrin in a context of inflammation-induced pathology

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Kruzel, Marian L ^a   Zimecki, Michal ^b   Actor, Jeffrey K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Immunopathology; Immunotherapy; Inflammation; Lactoferrin; Pathology

Indexed keywords

CATALASE; CD22 ANTIGEN; GLUTATHIONE PEROXIDASE; HEAT SHOCK PROTEIN; HYDROGEN PEROXIDE; INFLAMMASOME; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

APOPTOSIS; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; DISEASE COURSE; ENDOTOXEMIA; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; LIPID PEROXIDATION; LUNG INJURY; OXIDATION; OXIDATIVE STRESS; RESPIRATORY TRACT INFLAMMATION; REVIEW; TISSUE INJURY; TUBERCULOSIS;

EID: 85034027512     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01438     Document Type: Review

References (156)

1. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des (2009) 15:1956-73. doi:10.2174/138161209788453202
2. Kruzel ML, Actor JK, Boldogh I, Zimecki M. Lactoferrin in health and disease. Postepy Hig Med Dosw (2007) 61:261-7
3. Baker EN, Anderson BF, Baker HM, Day CL, Haridas M, Norris GE, et al. Three-dimensional structure of lactoferrin in various functional states. Adv Exp Med Biol (1994) 357:1-12. doi:10.1007/978-1-4615-2548-6_1
4. Kruzel ML, Zimecki M. Lactoferrin and immunologic dissonance: clinical implications. Arch Immunol Ther Exp (2002) 50:399-410
5. Samyn-Petit B, Wajda Dubos JP, Chirat F, Coddeville B, Demaizieres G, Farrer S, et al. Comparative analysis of the site-specific N-glycosylation of human lactoferrin produced in maize and tobacco plants. Eur J Biochem (2003) 270:3235-42. doi:10.1046/j.1432-1033.2003.03706.x
6. Karav S, German JB, Rouquie C, Le Parc A, Barile D. Studying lactoferrin N-glycosylation. Int J Mol Sci (2017) 18(4):870. doi:10.3390/ijms18040870
7. Choi BK, Actor JK, Rios S, d'Anjou M, Stadheim TA, Warburton S, et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J (2008) 25:581-93. doi:10.1007/s10719-008-9123-y
8. Zimecki M, Artym J, Kocieba M, Duk M, Kruzel ML. The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro. Cell Mol Biol Lett (2014) 19:284-96. doi:10.2478/s11658-014-0196-2
9. Zimecki M, Artym J, Kocieba M, Kaleta-Kuratewicz K, Kuropka P, Kuryszko J, et al. Homologous lactoferrin triggers mobilization of the myelocytic lineage of bone marrow in experimental mice. Stem Cells Dev (2013) 22:3261-70. doi:10.1089/scd.2013.0242
10. Francis N, Wong SH, Hampson P, Wang K, Young SP, Deigner HP, et al. Lactoferrin inhibits neutrophil apoptosis via blockade of proximal apoptotic signaling events. Biochim Biophys Acta (2011) 1813:1822-6. doi:10.1016/j.bbamcr.2011.07.004
11. Okubo K, Kamiya M, Urano Y, Nishi H, Herter JM, Mayadas T, et al. Lactoferrin suppresses neutrophil extracellular traps release in inflammation. EBioMedicine (2016) 10:204-15. doi:10.1016/j.ebiom.2016.07.012
12. Lonnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr (1995) 15:93-110. doi:10.1146/annurev.nu.15.070195.000521
13. Sanchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch Dis Child (1992) 67:657-61. doi:10.1136/adc.67.5.657
14. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med (1999) 37:281-6. doi:10.1515/CCLM.1999.049
15. Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol (1994) 357:133-41. doi:10.1007/978-1-4615-2548-6_13
16. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol (2002) 130:25-31. doi:10.1046/j.1365-2249.2002.01956.x
17. Manzoni P, Decembrino L, Stolfi I, Pugni L, Rinaldi M, Cattani S, et al. Lactoferrin and prevention of late-onset sepsis in the pre-term neonates. Early Hum Dev (2010) 86(Suppl 1):59-61. doi:10.1016/j.earlhumdev.2010.01.009
18. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA (2009) 302:1421-8. doi:10.1001/jama.2009.1403
19. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g. Pediatr Infect Dis J (2015) 34:571-6. doi:10.1097/INF.0000000000000593
20. Kruzel ML, Harari Y, Chen CY, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation (2000) 24:33-44. doi:10.1023/A:1006935908960
21. Ochoa TJ, Chea-Woo E, Baiocchi N, Pecho I, Campos M, Prada A, et al. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. J Pediatr (2013) 162:349-56. doi:10.1016/j.jpeds.2012.07.043
22. Ochoa TJ, Pezo A, Cruz K, Chea-Woo E, Cleary TG. Clinical studies of lactoferrin in children. Biochem Cell Biol (2012) 90:457-67. doi:10.1139/o11-087
23. Fine DH, Toruner GA, Velliyagounder K, Sampathkumar V, Godboley D, Furgang D. A lactotransferrin single nucleotide polymorphism demonstrates biological activity that can reduce susceptibility to caries. Infect Immun (2013) 81:1596-605. doi:10.1128/IAI.01063-12
24. Mohamed JA, DuPont HL, Jiang ZD, Belkind-Gerson J, Figueroa JF, Armitige LY, et al. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis (2007) 44:945-52. doi:10.1086/512199
25. Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun (1998) 66:486-91
26. Okazaki Y, Kono I, Kuriki T, Funahashi S, Fushimi S, Iqbal M, et al. Bovine lactoferrin ameliorates ferric nitrilotriacetate-induced renal oxidative damage in rats. J Clin Biochem Nutr (2012) 51:84-90. doi:10.3164/jcbn.11-100
27. Baynes R, Bezwoda W, Bothwell T, Khan Q, Mansoor N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest (1986) 46:695-704. doi:10.3109/00365518609083733
28. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol (2008) 180:6868-76. doi:10.4049/jimmunol.180.10.6868
29. Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins initiate host defense. Adv Exp Med Biol (2007) 601:185-94. doi:10.1007/978-0-387-72005-0_19
30. Yang D, de la Rosa G, Tewary P, Oppenheim JJ. Alarmins link neutrophils and dendritic cells. Trends Immunol (2009) 30:531-7. doi:10.1016/j.it.2009.07.004
31. Hwang SA, Wilk KM, Bangale YA, Kruzel ML, Actor JK. Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol (2007) 196:171-80. doi:10.1007/s00430-007-0041-6
32. Zimecki M, Artym J, Chodaczek G, Kocieba M, Kuryszko J, Houszka M, et al. Immunoregulatory function of lactoferrin in immunosuppressed and autoimmune animals. Postepy Hig Med Dosw (2007) 61:283-7
33. Zimecki M, Kruzel ML. Milk-derived proteins and peptides of potential therapeutic and nutritive value. J Exp Ther Oncol (2007) 6:89-106
34. Zimecki M, Mazurier J, Spik G, Kapp JA. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology (1995) 86:122-7
35. Zimecki M, Miedzybrodzki R, Mazurier J, Spik G. Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch Immunol Ther Exp (1999) 47:257-64
36. Hwang SA, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int Immunopharmacol (2005) 5:591-9. doi:10.1016/j.intimp.2004.11.006
37. Artym J, Zimecki M, Kruzel ML. Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice. Anticancer Res (2004) 24:3831-6
38. Kruzel ML, Bacsi A, Choudhury B, Sur S, Boldogh I. Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology (2006) 119:159-66. doi:10.1111/j.1365-2567.2006.02417.x
39. Kuhara T, Tanaka A, Yamauchi K, Iwatsuki K. Bovine lactoferrin ingestion protects against inflammation via IL-11 induction in the small intestine of mice with hepatitis. Br J Nutr (2014) 111:1801-10. doi:10.1017/S0007114513004315
40. Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, et al. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol (2002) 17:1291-8. doi:10.1046/j.1440-1746.2002.02868.x
41. Welsh KJ, Hwang SA, Boyd S, Kruzel ML, Hunter RL, Actor JK. Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberculosis (2011) 91(Suppl 1):S105-13. doi:10.1016/j.tube.2011.10.019
42. Welsh KJ, Hwang SA, Hunter RL, Kruzel ML, Actor JK. Lactoferrin modulation of mycobacterial cord factor trehalose 6-6'-dimycolate induced granulomatous response. Transl Res (2010) 156:207-15. doi:10.1016/j.trsl.2010.06.001
43. Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol (2012) 90:233-44. doi:10.1139/o2012-016
44. Legrand D. Overview of lactoferrin as a natural immune modulator. J Pediatr (2016) 173(Suppl):S10-5. doi:10.1016/j.jpeds.2016.02.071
45. Baker EN, Baker HM. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie (2009) 91:3-10. doi:10.1016/j.biochi.2008.05.006
46. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol (2008) 606:163-94. doi:10.1007/978-0-387-74087-4_6
47. Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie (2009) 91:11-8. doi:10.1016/j.biochi.2008.05.005
48. Legrand D, Elass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol (2006) 84:282-90. doi:10.1139/o06-045
49. Mayeur S, Spahis S, Pouliot Y, Levy E. Lactoferrin, a pleiotropic protein in health and disease. Antioxid Redox Signal (2016) 24:813-36. doi:10.1089/ars.2015.6458
50. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 10:826-37. doi:10.1038/nri2873
51. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 171:715-27. doi:10.2353/ajpath.2007.070166
52. Calame DG, Mueller-Ortiz SL, Wetsel RA. Innate and adaptive immunologic functions of complement in the host response to Listeria monocytogenes infection. Immunobiology (2016) 221:1407-17. doi:10.1016/j.imbio.2016.07.004
53. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (2010) 330:362-6. doi:10.1126/science.1195491
54. Sangiuliano B, Perez NM, Moreira DF, Belizario JE. Cell death-associated molecular-pattern molecules: inflammatory signaling and control. Mediators Inflamm (2014) 2014:821043. doi:10.1155/2014/821043
55. He Y, Lawlor NT, Newburg DS. Human milk components modulate toll-like receptor-mediated inflammation. Adv Nutr (2016) 7:102-11. doi:10.3945/an.115.010090
56. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals (2010) 23:365-76. doi:10.1007/s10534-010-9297-1
57. Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and-independent signaling pathways. Cell Immunol (2006) 242:23-30. doi:10.1016/j.cellimm.2006.08.006
58. Drago-Serrano ME, de la Garza-Amaya M, Luna JS, Campos-Rodriguez R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol (2012) 12:1-9. doi:10.1016/j.intimp.2011.11.002
59. Zheng Y, Qin Z, Ye Q, Chen P, Wang Z, Yan Q, et al. Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9. Lab Invest (2014) 94:1188-99. doi:10.1038/labinvest.2014.105
60. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science (2001) 294:870-5. doi:10.1126/science.294.5543.870
61. Zemankova N, Chlebova K, Matiasovic J, Prodelalova J, Gebauer J, Faldyna M. Bovine lactoferrin free of lipopolysaccharide can induce a proinflammatory response of macrophages. BMC Vet Res (2016) 12:251. doi:10.1186/s12917-016-0878-2
62. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 27:693-733. doi:10.1146/annurev.immunol.021908.132641
63. Rainard P. Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology (1993) 79:648-52
64. Kievits F, Kijlstra A. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin. Immunology (1985) 54:449-56
65. Samuelsen O, Haukland HH, Ulvatne H, Vorland LH. Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol Med Microbiol (2004) 41:141-8. doi:10.1016/j.femsim.2004.02.006
66. Lopez-Boado YS, Espinola M, Bahr S, Belaaouaj A. Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity. J Immunol (2004) 172:509-15. doi:10.4049/jimmunol.172.1.509
67. Eipper S, Steiner R, Lesner A, Sienczyk M, Palesch D, Halatsch ME, et al. Lactoferrin is an allosteric enhancer of the proteolytic activity of cathepsin G. PLoS One (2016) 11:e0151509. doi:10.1371/journal.pone.0151509
68. Cutone A, Rosa L, Lepanto MS, Scotti MJ, Berlutti F, Bonaccorsi di Patti MC, et al. Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol (2017) 8:705. doi:10.3389/fimmu.2017.00705
69. Zimecki M, Kocieba M, Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology (2002) 205:120-31. doi:10.1078/0171-2985-00115
70. Kruzel ML, Actor JK, Zimecki M, Wise J, Ploszaj P, Mirza S, et al. Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression. J Biotechnol (2013) 168:666-75. doi:10.1016/j.jbiotec.2013.09.011
71. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis (2000) 21:361-70. doi:10.1093/carcin/21.3.361
72. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry (2000) 39:6951-9. doi:10.1021/bi000169p
73. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost (1999) 82(Suppl 1):32-7
74. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life (2000) 50:315-21. doi:10.1080/713803726
75. Kruzel ML, Actor JK, Radak Z, Bacsi A, Saavedra-Molina A, Boldogh I. Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun (2010) 16:67-79. doi:10.1177/1753425909105317
76. Zhang AS, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem (2009) 284:711-5. doi:10.1074/jbc.R800017200
77. Zimecki M, Wieczorek Z, Kapp JA, Pierce CW. Structures on T cells and macrophages involved in interleukin 1 (Il-1) secretion by macrophages upon contact with syngeneic thymocytes. Arch Immunol Ther Exp (1989) 37:587-92
78. Zupin L, Angelelli F, Grasso DL, Crovella S. Lactoferrin gene polymorphisms in Italian patients with recurrent tonsillitis. Int J Pediatr Otorhinolaryngol (2016) 88:153-6. doi:10.1016/j.ijporl.2016.07.002
79. Fine DH. Lactoferrin: a roadmap to the borderland between caries and periodontal disease. J Dent Res (2015) 94:768-76. doi:10.1177/0022034515577413
80. Barber MF, Kronenberg Z, Yandell M, Elde NC. Antimicrobial functions of lactoferrin promote genetic conflicts in ancient primates and modern humans. PLoS Genet (2016) 12:e1006063. doi:10.1371/journal.pgen.1006063
81. Zimecki M, Wlaszczyk A, Zagulski T, Kubler A. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery. Arch Immunol Ther Exp (1998) 46:97-104
82. Zimecki M, Wlaszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp (2001) 49:325-33
83. Puddu P, Latorre D, Carollo M, Catizone A, Ricci G, Valenti P, et al. Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells. PLoS One (2011) 6:e22504. doi:10.1371/journal.pone.0022504
84. Tang L, Wu JJ, Ma Q, Cui T, Andreopoulos FM, Gil J, et al. Human lactoferrin stimulates skin keratinocyte function and wound re-epithelialization. Br J Dermatol (2010) 163:38-47. doi:10.1111/j.1365-2133.2010.09748.x
85. Uehara A, Sugawara Y, Kurata S, Fujimoto Y, Fukase K, Kusumoto S, et al. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Cell Microbiol (2005) 7:675-86. doi:10.1111/j.1462-5822.2004.00500.x
86. Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, et al. Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. FASEB J (2014) 28:416-29. doi:10.1096/fj.13-229591
87. Novak N, Allam JP. Mucosal dendritic cells in allergy and immunotherapy. Allergy (2011) 66(Suppl 95):22-4. doi:10.1111/j.1398-9995.2011.02626.x
88. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol (2000) 164:966-72. doi:10.4049/jimmunol.164.2.966
89. Hayashi T, To M, Saruta J, Sato C, Yamamoto Y, Kondo Y, et al. Salivary lactoferrin is transferred into the brain via the sublingual route. Biosci Biotechnol Biochem (2017) 81:1300-4. doi:10.1080/09168451.2017.1308241
90. Ginet V, van de Looij Y, Petrenko V, Toulotte A, Kiss J, Huppi PS, et al. Lactoferrin during lactation reduces lipopolysaccharide-induced brain injury. Biofactors (2016) 42:323-36. doi:10.1002/biof.1278
91. Artym J, Kocieba M, Zaczynska E, Adamik B, Kubler A, Zimecki M, et al. Immunomodulatory properties of human recombinant lactoferrin in mice and their implications for therapeutic use in humans. Int Immunopharmacol (2014) 20(1):157-63. doi:10.1016/j.intimp.2014.02.029
92. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med (2008) 26:711-5. doi:10.1016/j.ajem.2007.10.031
93. Oviedo-Boyso J, Bravo-Patino A, Baizabal-Aguirre VM. Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria. Mediators Inflamm (2014) 2014:432785. doi:10.1155/2014/432785
94. Exline MC, Crouser ED. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci (2008) 13:5030-41
95. Shapiro L, Gelfand JA. Cytokines and sepsis: pathophysiology and therapy. New Horiz (1993) 1:13-22
96. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 16:379-414. doi:10.1128/CMR.16.3.379-414.2003
97. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg (1992) 216:117-34. doi:10.1097/00000658-199208000-00002
98. Deitch EA. Role of bacterial translocation in necrotizing enterocolitis. Acta Paediatr (1994) 396:33-6. doi:10.1111/j.1651-2227.1994.tb13239.x
99. Nadler EP, Upperman JS, Dickinson EC, Ford HR. Nitric oxide and intestinal barrier failure. Semin Pediatr Surg (1999) 8:148-54. doi:10.1016/S1055-8586(99)70016-8
100. DeMaria EJ, Dalton J. Bacterial translocation and the release of endotoxin and cytokines following trauma. In: Sugerman HJ, DeMaria EJ, editors. Cytokines in Trauma and Hemorrhage. Portland, OR: Chapman & Hall (1997). p. 43-61
101. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol (1989) 70:697-704
102. Godinez-Victoria M, Cruz-Hernandez TR, Reyna-Garfias H, Barbosa-Cabrera RE, Drago-Serrano ME, Sanchez-Gomez MC, et al. Modulation by bovine lactoferrin of parameters associated with the IgA response in the proximal and distal small intestine of BALB/c mice. Immunopharmacol Immunotoxicol (2017) 39:66-73. doi:10.1080/08923973.2017.1282513
103. Doursout MF, Horton H, Hoang L, Liang Y, Hwang SA, Boyd S, et al. Lactoferrin moderates LPS-induced hypotensive response and gut injury in rats. Int Immunopharmacol (2013) 15:227-31. doi:10.1016/j.intimp.2012.12.009
104. Artym J, Zimecki M, Kruzel ML. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int Immunopharmacol (2004) 4:1149-57. doi:10.1016/j.intimp.2004.05.002
105. Zimecki M, Artym J, Chodaczek G, Kocieba M, Kruzel ML. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res (2004) 53:292-6. doi:10.1007/s00011-004-1257-1
106. Zimecki M, Chodaczek G, Kocieba M, Kruzel ML. Lethality in LPS-induced endotoxemia in C3H/HeCr mice is associated with prevalence of proinflammatory cytokines: lack of protective action of lactoferrin. FEMS Immunol Med Microbiol (2004) 42:167-72. doi:10.1016/j.femsim.2004.04.003
107. Scott-Conner CE, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res (1994) 57:316-36. doi:10.1006/jsre.1994.1151
108. Zimecki M, Dawiskiba J, Zawirska B, Krawczyk Z, Kruzel M. Bovine lactoferrin decreases histopathological changes in the liver and regulates cytokine production by splenocytes of obstructive jaundiced rats. Inflamm Res (2003) 52:305-10. doi:10.1007/s00011-003-1178-4
109. Pena-Juarez MC, Campos-Rodriguez R, Godinez-Victoria M, Cruz-Hernandez TR, Reyna-Garfias H, Barbosa-Cabrera RE, et al. Effect of bovine lactoferrin treatment followed by acute stress on the IgA-response in small intestine of BALB/c mice. Immunol Invest (2016) 45:652-67. doi:10.1080/08820139.2016.1202959
110. Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol (2002) 283:G187-95. doi:10.1152/ajpgi.00331.2001
111. Li L, Ren F, Yun Z, An Y, Wang C, Yan X. Determination of the effects of lactoferrin in a preclinical mouse model of experimental colitis. Mol Med Rep (2013) 8:1125-9. doi:10.3892/mmr.2013.1632
112. MacManus CF, Collins CB, Nguyen TT, Alfano RW, Jedlicka P, de Zoeten EF. VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease. J Crohns Colitis (2017) 11(9):1101-12. doi:10.1093/ecco-jcc/jjx056
113. Zhang T, Wang Y, Ban R, Tong L, Qiao H, Lao H, et al. Oral administration of lactoferrin attenuates intestinal ischemia-reperfusion injury in rats. Eur Surg Res (2012) 49:99-106. doi:10.1159/000342633
114. Iigo M, Alexander DB, Xu J, Futakuchi M, Suzui M, Kozu T, et al. Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine. Biometals (2014) 27:1017-29. doi:10.1007/s10534-014-9747-2
115. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med (2000) 28:1456-62. doi:10.1016/S0891-5849(00)00252-5
116. Holgate ST. The epidemic of allergy and asthma. Nature (1999) 402:B2-4. doi:10.1038/35037000
117. Bacsi A, Dharajiya N, Choudhury BK, Sur S, Boldogh I. Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis. J Allergy Clin Immunol (2005) 116:836-43. doi:10.1016/j.jaci.2005.06.002
118. Boldogh I, Bacsi A, Choudhury BK, Dharajiya N, Alam R, Hazra TK, et al. ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. J Clin Invest (2005) 115:2169-79. doi:10.1172/JCI24422
119. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med (2004) 37:755-67. doi:10.1016/j.freeradbiomed.2004.05.034
120. Gutteridge JM, Mumby S, Quinlan GJ, Chung KF, Evans TW. Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in the lung. Biochem Biophys Res Commun (1996) 220:1024-7. doi:10.1006/bbrc.1996.0518
121. Mateos F, Brock JH, Perez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax (1998) 53:594-600. doi:10.1136/thx.53.7.594
122. Park YY, Hybertson BM, Wright RM, Repine JE. Serum ferritin increases in hemorrhaged rats that develop acute lung injury: effect of an iron-deficient diet. Inflammation (2003) 27:257-63. doi:10.1023/A:1025044732423
123. Zhao G I, Ayene S, Fisher AB. Role of iron in ischemia-reperfusion oxidative injury of rat lungs. Am J Respir Cell Mol Biol (1997) 16:293-9. doi:10.1165/ajrcmb.16.3.9070614
124. Zimecki M, Artym J, Kocieba M, Kaleta-Kuratewicz K, Kruzel ML. Lactoferrin restrains allergen-induced pleurisy in mice. Inflamm Res (2012) 61:1247-55. doi:10.1007/s00011-012-0522-y
125. Wang SB, Deng YQ, Ren J, Xiao BK, Chen Z, Tao ZZ. Lactoferrin administration into the nostril alleviates murine allergic rhinitis and its mechanisms. Scand J Immunol (2013) 78:507-15. doi:10.1111/sji.12118
126. Bournazou I, Mackenzie KJ, Duffin R, Rossi AG, Gregory CD. Inhibition of eosinophil migration by lactoferrin. Immunol Cell Biol (2010) 88:220-3. doi:10.1038/icb.2009.86
127. Actor JK. Lactoferrin: a modulator for immunity against tuberculosis related granulomatous pathology. Mediators Inflamm (2015) 2015:409596. doi:10.1155/2015/409596
128. Zimecki M, Mazurier J, Machnicki M, Wieczorek Z, Montreuil J, Spik G. Immunostimulatory activity of lactotransferrin and maturation of CD4-CD8-murine thymocytes. Immunol Lett (1991) 30:119-23. doi:10.1016/0165-2478(91)90099-V
129. Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C. A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med Microbiol Immunol (2006) 195:207-16. doi:10.1007/s00430-006-0020-3
130. Hwang SA, Welsh KJ, Boyd S, Kruzel ML, Actor JK. Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen. Tuberculosis (2011) 91(Suppl 1):S90-5. doi:10.1016/j.tube.2011.10.017
131. Hwang SA, Welsh KJ, Kruzel ML, Actor JK. Lactoferrin augmentation of the BCG vaccine leads to increased pulmonary integrity. Tuberc Res Treat (2011) 2011:835410. doi:10.1155/2011/835410
132. Hwang SA, Wilk K, Kruzel ML, Actor JK. A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice. Vaccine (2009) 27:3026-34. doi:10.1016/j.vaccine.2009.03.036
133. Hwang SA, Arora R, Kruzel ML, Actor JK. Lactoferrin enhances efficacy of the BCG vaccine: comparison between two inbred mice strains (C57BL/6 and BALB/c). Tuberculosis (2009) 89(Suppl 1):S49-54. doi:10.1016/S1472-9792(09)70012-5
134. Zimecki M, Wieczorek Z, Mazurier J, Spik G. Lactoferrin lowers the incidence of positive Coombs' test in New Zealand black mice. Arch Immunol Ther Exp (1995) 43:207-9
135. Zimecki M, Webb DR Jr. The role of prostaglandins in the control of the immune response to an autologous red blood cell antigen (Hb). Clin Immunol Immunopathol (1977) 8:420-9. doi:10.1016/0090-1229(77)90006-X
136. Zimecki M, Kocieba M, Chodaczek G, Houszka M, Kruzel ML. Lactoferrin ameliorates symptoms of experimental encephalomyelitis in Lewis rats. J Neuroimmunol (2007) 182:160-6. doi:10.1016/j.jneuroim.2006.10.008
137. Kruzel M, Artym J, Chodaczek G, Kocieba M, Kochanowska I, Kruzel T, et al. Effects of lactoferrin on stress-related immune dysfunction in mice and humans. Proceedings of the 4th International Whey Conference; Chicago, IL, USA. (2005). p. 121-32
138. Lin TY, Kuo CD. Bovine lactoferrin protects RSC96 Schwann cells from tumor necrosis factor-alpha-induced growth arrest via extracellular-signal-regulated kinase 1/2. Neuroscience (2008) 151:396-402. doi:10.1016/j.neuroscience.2007.10.018
139. Zimecki M, Mazurier J, Spik G, Kapp JA. Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch Immunol Ther Exp (1996) 44:51-6
140. Zimecki M, Artym J, Kocieba M, Kruzel M. Effects of lactoferrin on elicitation of the antigen-specific cellular and humoral cutaneous response in mice. Postepy Hig Med Dosw (2012) 66:16-22. doi:10.5604/17322693.975145
141. Yin H, Cheng L, Agarwal C, Agarwal R, Ju C. Lactoferrin protects against concanavalin A-induced liver injury in mice. Liver Int (2010) 30:623-32. doi:10.1111/j.1478-3231.2009.02199.x
142. Koike D, Makino I. Protective effect of lactoferrin on caerulein-induced acute pancreatitis in rats. Digestion (1993) 54:84-90. doi:10.1159/000201018
143. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, et al. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology (2004) 145:4366-74. doi:10.1210/en.2003-1307
144. Hou JM, Xue Y, Lin QM. Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway. Acta Pharmacol Sin (2012) 33:1277-84. doi:10.1038/aps.2012.83
145. Inamori M, Togawa J, Matsumoto S, Harad K, Matsuura M, Iida H, et al. Protective effect of lactoferrin on acute acid reflux-induced esophageal mucosal damage. Hepatogastroenterology (2014) 61:1595-600
146. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol (1993) 74:433-9
147. Hwang SA, Wilk KM, Budnicka M, Olsen M, Bangale YA, Hunter RL, et al. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine (2007) 25:6730-43. doi:10.1016/j.vaccine.2007.07.005
148. Hwang S-A, Kruzel ML, Actor JK. Oral recombinant human or mouse lactoferrin reduces Mycobacterium tuberculosis TDM induced granulomatous lung pathology. Biochem Cell Biol (2017) 95(1):148-54. doi:10.1139/bcb-2016-0061
149. Naidu AS, Arnold RR. Lactoferrin interaction with salmonellae potentiates antibiotic susceptibility in vitro. Diagn Microbiol Infect Dis (1994) 20:69-75. doi:10.1016/0732-8893(94)90094-9
150. Fowler CE, Soothill JS, Oakes L. MICs of rifampicin and chloramphenicol for mucoid Pseudomonas aeruginosa strains are lower when human lactoferrin is present. J Antimicrob Chemother (1997) 40:877-9. doi:10.1093/jac/40.6.877
151. Sanchez MS, Watts JL. Enhancement of the activity of novobiocin against Escherichia coli by lactoferrin. J Dairy Sci (1999) 82:494-9. doi:10.3168/jds.S0022-0302(99)75259-8
152. Zimecki M, Artym J, Kocieba M, Weber-Dabrowska B, Lusiak-Szelachowska M, Gorski A. The concerted action of lactoferrin and bacteriophages in the clearance of bacteria in sublethally infected mice. Postepy Hig Med Dosw (2008) 62:42-6
153. Ochoa TJ, Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie (2009) 91:30-4. doi:10.1016/j.biochi.2008.04.006
154. Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, et al. Antiviral properties of lactoferrin-a natural immunity molecule. Molecules (2011) 16:6992-7018. doi:10.3390/molecules16086992
155. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci (2005) 62:2576-87. doi:10.1007/s00018-005-5372-0
156. Hwang SA, Kruzel ML, Actor JK. Immunomodulatory effects of recombinant lactoferrin during MRSA infection. Int Immunopharmacol (2014) 20:157-63. doi:10.1016/j.intimp.2014.02.029